Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 80Neoplasm Metastasis 6Neoplasms 3Breast Neoplasms, Male 3Arthralgia 2Triple Negative Breast Neoplasms 1Sleep Wake Disorders 1Skin Diseases 1Prostatic Neoplasms 1Post Menopausal Women With Early Breast Cancer 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Obesity 1Metastatic Beast Cancer 1Mammary Neoplasms, Animal 1Lymphoma 1Lethal Congenital Contracture Syndrome 2 1Invasive Early Breast Cancer 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Fatigue 1Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Advanced Breast Carcinoma 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Breast Carcinoma × exemestane × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡